TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11346146
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b 5 Million Units thrice weekly (group B)
Study: 11346146
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b 5 Million Units daily (group C)
Study: 9876054
Drug: Amoxycillin/clavulanate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate (250 mg/62 mg t.i.d. or 125 mg/31 mg t.i.d. if aged under 6 years) for 7 days
Study: 9876054
Drug: Cefaclor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (250 mg t.i.d. or 125 mg t.i.d. if aged under 6 years) for 7 days
Study: 2491982
Drug: Adjusted probabilities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted probabilities of discontinuation for ICD
Study: 2491982
Drug: Adjusted probabilities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted probabilities of discontinuation for LNG‐IUD
Study: 2491982
Drug: Adjusted probabilities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted probabilities of discontinuation for Nova‐T
Study: 31760109
Drug: Integrated psychosocial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated psychosocial treatment (Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention)
Study: 31760109
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care through a Veteran's Administration co‐occurring disorders medical clinic
Study: 27908210
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal contraceptive (COC) containing 0.020 mg of ethynyl estradiol (EE)
Study: 27908210
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal contraceptive (COC) containing 0.030 mg of ethynyl estradiol (EE)
Study: 27908210
Drug: Natural COC
Normalized name: GLYCERIN 6 g in 100 mL TOPICAL SOLUTION [Natural Cocktail Pack]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural COC containing 1.5 mg of estradiol (E2)
Study: 27908210
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring releasing 0.015 mg of EE + 0.120 mg of etonogestrel
Study: 27908210
Drug: Progestin only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin only subcutaneous contraceptive implant releasing etonogestrel
Study: 25425394
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300U/ml (Gla‐300) administered at a dosage of 0.4U/kg once daily for six days
Study: 25425394
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300U/ml (Gla‐300)
Study: 23778372
Drug: Usual chiropractic
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual chiropractic treatment
Study: 19261771
Drug: wP vaccine
Normalized name: WP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: wP vaccine
Study: 19261771
Drug: wP(low) vaccine
Normalized name: WP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: wP(low) vaccine
Study: 16954234
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with both GBV-C E2 antibody and viremia
Study: 11332870
Drug: Piracetam treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam treatment
Study: 30290629
Drug: Gel cushion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel cushion
Study: 23871316
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and maxillofacial surgeon
Study: 22002111
Drug: Intraprostatic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injection of epinephrine
Study: 22002111
Drug: Intraprostatic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injection of saline solution (placebo)
Study: 18261506
Drug: Paroxetine controlled‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled‐release (12.5‐25 mg/d)
Study: 11575418
Drug: Inhaled isoflurane
Normalized name: isoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoflurane at end‐tidal concentration 1‐1.5% (group I, n=20)
Study: 11575418
Drug: Target‐controlled infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target‐controlled infusion (TCI) of propofol at target concentration 2‐5 microg ml(‐1) (group P, n=18)
Study: 9932224
Drug: Biological tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological tests before clinical symptoms
Study: 8060926
Drug: Candoxatril 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 200 mg twice daily for 4 weeks
Study: 26246480
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral steroid administration
Study: 26246480
Drug: Endoscopic local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic local steroid injection
Study: 23831870
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampin (600 mg)
Study: 19401528
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (13‐cis RA and 13‐cis RA/alpha tocopherol)
Study: 12577389
Drug: Compound Aspirin
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Aspirin (APC)
Study: 9359049
Drug: High-dose dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dipyridamole (up to 0.84 mg/kg over 10')
Study: 9359049
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (up to 10 mcg/kg/min)
Study: 8000787
Drug: Leptospirosis vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptospirosis vaccine
Study: 23240711
Drug: Alcohol infusion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol infusion (target breath alcohol concentration = 0.06 g/dl)
Study: 28675116
Drug: Alcohol infusion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol infusion
Study: 22022215
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride vapocoolant spray
Study: 19691847
Drug: Temporary fracture
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary fracture fixation with fixateur externe and defined secondary definitive treatment (DCO)
Study: 15614996
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phase synchronization measures with alpha power spectral density estimates
Study: 8068482
Drug: Intramuscular recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular recombinant IFN alpha‐2b
Study: 3711577
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1% tropicamide and 2.5% phenylephrine
Study: 21865014
Drug: Active Treatment
Normalized name: Active
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Treatment (AT)
Study: 22235841
Drug: Formoterol 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 9 μg via Turbuhaler®
Study: 22235841
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 μg via Diskus®
Study: 18827613
Drug: Dose-dense docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim without BNP7787 (Group A)
Study: 18827613
Drug: Dose-dense docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim with BNP7787 (Group B)
Study: 16408240
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airways pressure therapy (CPAP)
Study: 10798794
Drug: Loprazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loprazolam (2 mg)
Study: 9275691
Drug: Osmosis chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmosis chemotherapy (5-FU)
Study: 26762482
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% rebamipide
Study: 26762482
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment with rebamipide)
Study: 24583430
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (5-15 mg/day of prednisolone and 6 mg/week of methotrexate)
Study: 21059430
Drug: Hemoglobin level
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin level <120 g/L
Study: 21059430
Drug: Hemoglobin level
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin level 120 to 139 g/L
Study: 21059430
Drug: Hemoglobin level
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin level 140 to 159 g/L
Study: 21059430
Drug: Hemoglobin level
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin level >160 g/L
Study: 10599988
Drug: [1‐(13)C]KIC infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: [1‐(13)C]KIC infusion
Study: 10599988
Drug: [5,5,5‐2H3]KIC infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: [5,5,5‐2H3]KIC infusion
Study: 1663282
Drug: 4-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug combination of 7-10 mg/kg rifabutin, 5 mg/kg isoniazid, 20 mg/kg ethambutol and 100 mg clofazimine
Study: 6136959
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose isosorbide dinitrate in combination with nadolol
Study: 6136959
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose nifedipine in combination with nadolol
Study: 6136959
Drug: Nadolol alone
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol alone and in combination with isosorbide dinitrate or nifedipine
Study: 6136959
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose nifedipine
Study: 6136959
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate in combination with nadolol
Study: 6136959
Drug: Isosorbide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide treatment periods
Study: 28674765
Drug: TAC (triplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (triplet chemotherapy)
Study: 22744970
Drug: α(1)‐adrenoreceptor blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: α(1)‐adrenoreceptor blockade with prazosin (0.05 mg/kg)
Study: 15061656
Drug: Standard micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard micronutrient supplementation in patients under long term parenteral nutrition
Study: 11785713
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of ranitidine bismuth citrate 400 mg bid, clarithromycin 500 mg bid, and tinidazole 500 mg bid
Study: 11785713
Drug: 10-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day course of omeprazole 20 mg bid plus amoxycillin 1 g bid for the first 5 days, and omeprazole 20 mg bid, clarithromycin 500 mg bid and tinidazole 500 mg bid for the remaining 5 days
Study: 9408064
Drug: Cyclical oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical oral clodronate with calcium supplementation
Study: 3896664
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pirazolac in the morning and 600 mg at night
Study: 3896664
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg pirazolac given morning and evening
Study: 29143534
Drug: Quetiapine-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine-based treatment
Study: 23867841
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg daily for 6 months)
Study: 22779096
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% lotion
Study: 18330677
Drug: Adalimumab 20
Normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 20 mg
Study: 18831744
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg
Study: 8831326
Drug: Smaller doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller doses of each drug
Study: 8831326
Drug: Larger doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger doses of each drug
Study: 31907860
Drug: Tailored triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored triple therapy (TATT)
Study: 31907860
Drug: Traditional bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional bismuth-containing quadruple therapy (TRBQT)
Study: 31907860
Drug: Tailored bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored bismuth-containing quadruple therapy (TABQT)
Study: 28946832
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy plus medical management
Study: 26508752
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis only
Study: 23570501
Drug: E-CMF (epirubicin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-CMF (epirubicin-containing chemotherapy)
Study: 17133300
Drug: Oral yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral yohimbine
Study: 12733777
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances
Study: 10325911
Drug: Beta agonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta agonist reduction group (terbutaline dose reduced from 2500 to 500 micrograms/day)
Study: 10325911
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (terbutaline dose reduced from 3000 to 2250 micrograms/day)
Study: 7573829
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with depot grass pollen extract (Phleum pratense, Alutard SQ)
Study: 7573829
Drug: Continued injection
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued injection treatment (immunotherapy)
Study: 2109658
Drug: L-deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl (10 mg/day)
Study: 6110955
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin and chlorambucil
Study: 6110955
Drug: Low-dose cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose cisplatin, chlorambucil, and doxorubicin
Study: 27737714
Drug: Mindfulness-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based Cognitive Therapy (MBCT)
Study: 20961444
Drug: Maintenance anti-depressant
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance anti-depressant treatment (m-ADM)
Study: 7141754
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg rectal pretreatment)
Study: 7141754
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (300 mg)
Study: 31924519
Drug: Early rehabilitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rehabilitation (immediate physical therapy for passive and active ROM)
Study: 30036672
Drug: Clofazimine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine (100 mg per day)
Study: 23377024
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg (no caffeine) with 4.3% alcohol
Study: 23377024
Drug: Caffeine 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 62.5 mg with 4.3% alcohol
Study: 23377024
Drug: Caffeine 125
Normalized name: caffeine 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 125 mg with 4.3% alcohol
Study: 23377024
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg (no caffeine) with no alcohol
Study: 23377024
Drug: Caffeine 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 62.5 mg with no alcohol
Study: 23377024
Drug: Caffeine 125
Normalized name: caffeine 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 125 mg with no alcohol
Study: 19767090
Drug: Oestrogen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen plus progestin (0.625 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate)
Study: 17573745
Drug: Parenteral Gln
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Gln (1 g/kg/day) with enteral nutrition (Ensure)
Study: 14739803
Drug: Ketamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine at 200 ng/ml (analgesic, subanesthetic)
Study: 14739803
Drug: Ketamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine at 50 ng/ml (subanalgesic)
Study: 20102918
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg twice daily
Study: 8507122
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg twice daily
Study: 8507122
Drug: Cholestyramine 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 24 g daily
Study: 8507122
Drug: Cholestyramine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 12 g twice daily with Pravastatin 40 mg
Study: 8507122
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 or 80 mg daily
Study: 8507122
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Cholestyramine + Pravastatin)
Study: 29996833
Drug: Post-discharge malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge malaria chemoprevention (PMC) with antimalarial drugs for 3 months post-discharge.
Study: 29996833
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of health cards for treatment reminders.
Study: 29996833
Drug: Dihydroartemisinin-piperaquine as
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine as the antimalarial drug.
Study: 18480672
Drug: Upstream tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upstream tirofiban therapy
Study: 18480672
Drug: Downstream tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Downstream tirofiban therapy
Study: 18480672
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (primary PCI treatment alone)
Study: 14520850
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg twice a day
Study: 14520850
Drug: Metoprolol 25-50
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 25-50 mg twice a day
Study: 14520850
Drug: Bisoprolol 5-10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5-10 mg once a day
Study: 11755543
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (n = 105)
Study: 9371346
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (saquinavir, zidovudine, zalcitabine)
Study: 9371346
Drug: Saquinavir and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir and zidovudine combination
Study: 1531855
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) combined with chemotherapy
Study: 28202885
Drug: Conventional diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuretic therapy
Study: 31663690
Drug: Dexmedetomidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (2 μg kg‐1 perioperatively)
Study: 25201095
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy (therapy dog visitation for 15 minutes before physical therapy)
Study: 25201095
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative physical therapy regimens